Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
作者:Chutian Shu、Hu Ge、Michael Song、Jyun-hong Chen、Huimin Zhou、Qu Qi、Feng Wang、Xifeng Ma、Xiaolei Yang、Genyan Zhang、Yanwei Ding、Dapeng Zhou、Peng Peng、Cheng-kon Shih、Jun Xu、Frank Wu
DOI:10.1021/ml5001905
日期:2014.8.14
We report our discovery of a novel series of potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Starting from a lead identified by scaffold-hopping approach, our discovery and development efforts were focused on exploring structure-activity relationships, optimizing pharmacokinetic profile, improving in vitro and in vivo efficacy, and evaluating safety profile. The selected candidate
我们报告了我们发现的一系列新型的有效和选择性二肽基肽酶IV(DPP-4)抑制剂。从通过脚手架跳跃方法确定的线索开始,我们的发现和开发工作集中在探索结构与活性之间的关系,优化药代动力学特征,改善体外和体内功效以及评估安全性特征。选定的候选人伊米列汀目前正在接受临床试验。